SAILIFE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.3
| Stock Code | SAILIFE | Market Cap | 22,649 Cr. | Current Price | 1,069 ₹ | High / Low | 1,090 ₹ |
| Stock P/E | 67.6 | Book Value | 109 ₹ | Dividend Yield | 0.00 % | ROCE | 14.1 % |
| ROE | 11.0 % | Face Value | 1.00 ₹ | DMA 50 | 982 ₹ | DMA 200 | 902 ₹ |
| Chg in FII Hold | -0.24 % | Chg in DII Hold | 0.13 % | PAT Qtr | 104 Cr. | PAT Prev Qtr | 83.0 Cr. |
| RSI | 64.5 | MACD | 21.6 | Volume | 14,30,564 | Avg Vol 1Wk | 7,65,708 |
| Low price | 686 ₹ | High price | 1,090 ₹ | PEG Ratio | 0.28 | Debt to equity | 0.15 |
| 52w Index | 94.9 % | Qtr Profit Var | 103 % | EPS | 15.7 ₹ | Industry PE | 30.1 |
📊 SAILIFE shows strong earnings momentum with PAT growth of 103% QoQ and EPS of ₹15.7. The company maintains low leverage (Debt-to-equity: 0.15), which supports financial stability. However, valuations are expensive with a P/E of 67.6 compared to industry PE of 30.1, and ROE (11.0%) is moderate relative to premium pricing. Current price ₹1,069 is near its 52-week high (₹1,090), making ₹950–1,000 an ideal entry zone for long-term investors.
💡 Long-term investors may hold if profitability sustains and ROCE remains above 14%. Exit strategy: partial profit booking near ₹1,150–1,200 or full exit if ROE declines further or PEG ratio worsens. Dividend yield is 0.00%, so capital appreciation is the only driver.
Positive
- 📈 PAT growth of 103% QoQ shows strong earnings momentum.
- 💰 Debt-to-equity ratio of 0.15 indicates low leverage risk.
- 📊 EPS of ₹15.7 supports earnings visibility.
Limitation
- ⚠️ ROCE at 14.1% and ROE at 11% are moderate for long-term compounding.
- 📉 Dividend yield of 0.00% offers no passive income.
- 📊 High P/E of 67.6 compared to industry average of 30.1 indicates premium valuation.
Company Negative News
- 📉 FII holding declined (-0.24%), showing reduced foreign investor confidence.
- 📊 Valuation stretched with PEG ratio at 0.28, limiting upside.
Company Positive News
- 📈 PAT rose from ₹83 Cr. to ₹104 Cr., reflecting strong performance.
- 📊 DII holding increased (+0.13%), showing domestic institutional support.
Industry
- 🏭 Industry PE at 30.1 is much lower than SAILIFE’s 67.6, suggesting relative overvaluation.
- 📉 Pharma & life sciences sector is cyclical, tied to regulatory approvals and global demand.
Conclusion
⚖️ SAILIFE is a fundamentally strong company with robust earnings growth and low debt, but valuations are stretched compared to peers. Ideal entry is near ₹950–1,000. Long-term investors may hold for compounding benefits, but cautious monitoring of ROE and PEG ratio is essential. Exit near ₹1,150–1,200 or on deterioration of profitability metrics.
This structured HTML report captures SAILIFE’s fundamentals, valuation risks, and sector context with clear entry/exit guidance. Would you like me to extend this by benchmarking SAILIFE against peers such as Sun Pharma, Dr Reddy’s, or Cipla to highlight stronger alternatives in the pharma sector?